SKYE
Skye Bioscience, Inc.Company with tickers: SKYE
CIK
1516551
CUSIP
83086J200
Shares Outstanding
35,143,722
13F Activity (30d)
40 filings
38 filers
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $12,674,366 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| Research & Development | — | ||||
| Operating Income | $-12,674,366 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| Net Income | $-12,509,361 | USD | 2026-03-31 | 10-Q | 2026-05-11 |
| EPS (Basic) | $-0.32 | USD/shares | 2026-03-31 | 10-Q | 2026-05-11 |
| EPS (Diluted) | $-0.32 | USD/shares | 2026-03-31 | 10-Q | 2026-05-11 |